| psilocybin (COMP360) / Compass Pathways |
NCT06247839: The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder |
|
|
| Not yet recruiting | 3 | 20 | NA | Psilocybin | Massachusetts General Hospital, COMPASS Pathways | Major Depressive Disorder | 06/26 | 06/26 | | |
NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 255 | US | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 10/24 | 07/25 | | |
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD |
|
|
| Recruiting | 3 | 568 | Europe, Canada, US | Psilocybin, COMP360 | COMPASS Pathways | Treatment Resistant Depression | 03/25 | 05/25 | | |
2018-002577-22: The safety and efficacy of psilocybin as an adjunctive therapy in participants with treatment-resistant depression |
|
|
| Not yet recruiting | 2 | 20 | Europe | Psilocybin 5 mg, Capsule | COMPASS Pathfinder, Limited, COMPASS Pathfinder, Limited | treatment resistant depression, treatment resistant depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT04433845: The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. |
|
|
| Active, not recruiting | 2 | 15 | US | Psilocybin | Sheppard Pratt Health System, COMPASS Pathways | Treatment Resistant Depression | 01/23 | 04/23 | | |
2021-006233-19: Efficacy and safety of COMP360 psilocybin therapy in anorexia nervosa: a proof-of-concept study |
|
|
| Not yet recruiting | 2 | 60 | Europe | COMP360, Capsule | COMPASS Pathfinder Limited, COMPASS Pathfinder Limited | Anorexia Nervosa (AN), Anorexia Nervosa (AN), Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT04433858: An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD) |
|
|
| Active, not recruiting | 2 | 27 | US | Psilocybin | Sheppard Pratt Health System, COMPASS Pathways | Treatment Resistant Depression | 10/23 | 10/23 | | |
NCT05481736: Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study |
|
|
| Recruiting | 2 | 60 | Europe, US | Psilocybin, COMP360 | COMPASS Pathways | Anorexia Nervosa | 05/24 | 06/24 | | |
NCT05312151: The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder |
|
|
| Active, not recruiting | 2 | 22 | Europe, US | Psilocybin, COMP360 | COMPASS Pathways | Post Traumatic Stress Disorder | 12/23 | 04/24 | | |
NCT05220410: The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation |
|
|
| Recruiting | 2 | 20 | US | Psilocybin | Sheppard Pratt Health System, COMPASS Pathways | Treatment Resistant Depression, Suicidal Ideation | 04/24 | 04/24 | | |
NCT05733546: A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder |
|
|
| Recruiting | 2 | 102 | US | Psilocybin, COMP360 | COMPASS Pathways | Major Depressive Disorder | 10/24 | 11/24 | | |
| Not yet recruiting | 2 | 100 | US | Psilocybin, COMP360, Accelerated intermittent theta burst (aiTBS) rTMS treatment, Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), Stanford Neuromodulation Therapy (SNT), Low-dose psilocybin, low-dose COMP360, Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment, Sham Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), Sham Stanford Neuromodulation Therapy (SNT) | University of Texas at Austin | Treatment Resistant Depression, MDD, Major Depressive Disorder, Recurrent Depression, Depression | 03/27 | 05/27 | | |
NCT05381974: The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD |
|
|
| Withdrawn | 2 | 20 | US | Psilocybin | Massachusetts General Hospital, COMPASS Pathways | Treatment-Resistant Major Depressive Disorder | 06/23 | 06/23 | | |
NCT06258031: PsilOCD: A Pharmacological-Challenge Feasibility Study |
|
|
| Recruiting | 1 | 20 | Europe | Psilocybin (COMP360), O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine | Imperial College London | Obsessive-Compulsive Disorder | 06/24 | 07/24 | | |
| Recruiting | N/A | 70 | Europe | Psilocybin 5 mg, COMP360, Psilocybin 2 mg, Placebo | King's College London, University of Cambridge | Autism Spectrum Disorder | 09/25 | 09/25 | | |